Please assess the completion status of the following clinical trial:

Trial Title: Versartis Trial in Pre-pubertal Japanese Children With Growth Hormone Deficiency (GHD) to Assess Long-Acting Growth Hormone (Somavaratan, VRS-317)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Chronological Age ≥ 3.0 years and ≤ 9.0 years (girls) or ≤ 10.0 years (boys)~* Pre-pubertal status~* Diagnosis of GHD as documented by two or more GH stimulation test results~* Height SD score ≤ -2.0 at screening~* Weight for Stature ≥ 10th percentile~* IGF-I SD score ≤ -1.0 at screening~* Delayed bone age~Exclusion Criteria:~* Prior treatment with any growth promoting agent~* History of, or current, significant disease~* Chromosomal aneuploidy, significant gene mutations (other than those that cause GHD) or confirmed diagnosis of a named syndrome~* Birth weight and/or birth length less than 5th percentile for gestational age~* A diagnosis of Attention Deficit Hyperactivity Disorder~* Daily use of anti-inflammatory doses of glucocorticoid~* Prior history of leukemia, lymphoma, sarcoma or cancer~* Ocular findings suggestive of increased intracranial pressure and/or retinopathy at screening~* Significant spinal abnormalities including scoliosis, kyphosis and spina bifida variants~* Significant abnormality in screening laboratory studies

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 10 Years
- Healthy Volunteers: f

Study Arms:
- Phase 2: Somavaratan (VRS-317) (Type: EXPERIMENTAL): Active treatment arm
- Phase 3: Somavaratan (VRS-317) (Type: EXPERIMENTAL): Somavaratan long acting recombinant human growth hormone administered subcutaneously twice-monthly

Based on this trial design, predict the completion outcome and termination type (if applicable).